-
Story /The Novartis US Foundation has partnered with the Institute for Healthcare Improvement to help healthcare systems better serve patients.
-
Story /Novartis is fighting COVID-19 broadly, from committing R&D resources to better understand and treat the disease to reaching out to individuals and communities in need.
-
Story /More than 16 teams from US universities participated in the first US oncology data science hackathon to tackle current challenges in metastatic breast cancer treatments.
-
Story /Novartis is striving every day to help patients, strengthen communities, drive sustainability and build a more equitable healthcare system for all.
-
Story /After years of decline, cardiovascular disease mortality is on the rise, with a disproportionate impact on Black Americans
-
Story /Phil Gotwals talks about his vision for the future of business development for research.
-
Story /On this Day of Reflection, Novartis associates are thinking and talking about what it means to be part of a truly diverse and inclusive organization.
-
Media Release /East Hanover, March 28, 2023 — Updates to the NCCN Guidelines® for breast cancer, released in January 2023, recommend ribociclib (Kisqali®) as the only Category 1 preferred CDK4/6 inhibitor (…
-
Media Release /New approval based on TADPOLE trial showing overall response rate (ORR) of 47% and median progression-free survival (mPFS) of 20.1 months for Tafinlar + Mekinist compared to 11% ORR and 7.4 months…
Pagination
- ‹ Previous page
- 1
- …
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- …
- 83
- › Next page